摘要
A new screening strategy has been developed to select a new aptamer suitably used in a clinical environment by using an in vivo-like systematic evolution of ligands by exponential enrichment (SELEX) following by conventional position and negative selection processes. One novel methylation-specific aptamer with high affinity and high specificity was successfully selected such that it could capture methylated tumor circulating cell-free DNA (cfDNA) from plasma of ovarian cancer (OvCa) patients. The aptamer was conjugated onto magnetic beads and applied in an integrated microfluidic chip for detection and quantification of two methylated tumor suppressor genes, BRCA1/BRCA2, from cfDNA in plasma or blood. © 2023 IEEJ.